Company Overview
InfuSystem Holdings, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry by supplying electronic ambulatory infusion pumps and associated disposable products and services to markets in the United States and Canada. The business is structured into two distinct segments, Patient Services and Device Solutions, which collectively deliver the core operational infrastructure for the company's infusion therapy offerings. The organization employs a workforce of 461 individuals and maintains a market capitalization of $199.09M, reflecting its position as a mid-sized entity within the specialized medical technology landscape. This market cap, combined with annual revenue of $143.44M, indicates that the company has established a significant foothold but remains relatively small compared to large-cap healthcare conglomerates, suggesting a niche focus on specialized equipment rather than broad-market consumer goods.
Financial Health
The company reported revenue of $143.44M over the trailing twelve months, generating a net income of $6.63M and an EBITDA of $24.11M, highlighting a substantial difference between top-line growth and bottom-line profitability. This gap between revenue and net income reveals a cost structure where operating expenses, including cost of goods sold and overhead, consume a significant portion of earnings before interest and taxes, leaving a net profit margin that is notably lower than the gross margin. Free cash flow stands at $14.83M, which provides the company with essential financial flexibility to fund operations, maintain its asset base, and potentially pursue strategic initiatives without relying heavily on external capital markets. Analyzing the margins shows a gross margin of 56.0%, indicating strong pricing power or efficient manufacturing relative to direct costs, while an operating margin of 4.7% and a profit margin of 4.6% suggest that operating expenses are high enough to significantly compress the bottom line before interest and taxes. The balance sheet shows cash holdings of $3.19M against total debt of $24.44M, resulting in a debt-to-equity ratio of 42.63, which indicates a leveraged position where the company utilizes borrowed capital to finance its operations. Despite the debt load, the current ratio of 1.80 demonstrates adequate short-term liquidity, as current assets are sufficient to cover current liabilities with a comfortable buffer. Return on Equity is 11.5% and Return on Assets is 6.7%, metrics that reveal management's effectiveness in generating returns from shareholder equity and total assets respectively, though the ROA is lower than ROE due to the leverage present in the capital structure.
Valuation Assessment
Valuation multiples for InfuSystem Holdings, Inc. show a trailing P/E ratio of 31.58 and a forward P/E of 33.76, implying that the market expects earnings to grow slowly enough that the forward multiple is actually higher than the trailing multiple, or that current earnings are being re-rated. The price-to-book ratio stands at 3.45, indicating that the market values the company at a significant premium over its book value, which often reflects intangible assets or future growth potential not captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 1.39 and an EV/EBITDA of 9.09, suggesting that investors are willing to pay a moderate premium relative to sales while valuing earnings on a cash-flow basis at a level consistent with other mid-cap medical device firms. Price action over the last year has ranged between a 52-week high of $11.04 and a 52-week low of $4.61, providing context for the current trading range relative to historical volatility. The beta value of 1.63 indicates that the stock price is highly volatile relative to the broader market, moving with significantly greater intensity than the S&P 500.
Growth & Income
Revenue growth year-over-year is 7.0%, while earnings growth year-over-year is 123.9%, indicating that profitability is expanding at a much faster rate than sales, which often points to improved operational efficiency, mix shifts toward higher-margin products, or cost reductions. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning all earnings are retained within the business to fund growth initiatives rather than being distributed to shareholders. The absence of a dividend yield suggests the company prioritizes reinvestment in research, development, and expansion of its infusion pump portfolio to capitalize on market opportunities. Overall, the growth and income profile is characterized by high earnings acceleration and zero current income distribution, relying entirely on capital appreciation potential driven by internal growth dynamics and market share gains in the medical device sector.